AI assistant
FEEDBACK PLC — Major Shareholding Notification 2020
Jul 10, 2020
7636_mrq_2020-07-10_10602746-9e62-42a9-aeba-cec51a793518.html
Major Shareholding Notification
Open in viewerOpens in your device viewer
National Storage Mechanism | Additional information
RNS Number : 5980S
Feedback PLC
10 July 2020
Feedback plc
Holding in Company
London, 10 July 2020: Feedback plc (AIM: FDBK, "Feedback" or the "Company"), the specialist medical imaging technology company, announces that it has been advised that Premier Miton Investors is interested in 50,000,000 ordinary shares in the Company, representing 4.68 per cent. of the Company's issued share capital and voting rights.
Enquiries:
| Feedback plc Tom Oakley, CEO Lindsay Melvin, CFO |
+44 (0)1954 718072 [email protected] |
| Allenby Capital Limited (Nominated Adviser) David Worlidge / Asha Chotai |
+44 (0)20 3328 5656 |
| Peterhouse Capital Limited (Joint Broker) Lucy Williams / Duncan Vasey |
+44 (0)20 7469 0936 |
| Stanford Capital Partners Limited (Joint Broker) Patrick Claridge / John Howes |
+44 20 3815 8880 |
| Instinctif Partners Melanie Toyne-Sewell / Phillip Marriage |
+44 (0)20 7457 2020 +44 7890 022 814 [email protected] |
Notes to editors
About Feedback plc - www.fbk.com
Feedback plc (AIM: FDBK) is a specialist medical imaging technology company providing innovative software and systems, through its fully-owned trading subsidiary, Feedback Medical Limited. Its products advance the work of radiologists, clinicians and medical researchers by improving workflows and giving unique insights into diseases, particularly cancer.
Feedback has launched Bleepa, a new secure, encrypted medical communication app for clinicians accessible through smartphones, tablets and desktops that facilitates rapid clinical messaging and review of medical grade imaging for all members of a clinical team, directly from a hospital Picture Archiving and Communications System (PACS). For more information on BleepaⓇ, see www.bleepa.com.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
END
HOLSSUFMUESSEIW